Javascript must be enabled to continue!
Major depressive disorder and generalized anxiety disorder and response to treatment in hepatitis C patients in Egypt
View through CrossRef
Objectives
The aim of the study was to estimate the prevalence and associated correlates of major depressive disorder and generalized anxiety disorder in hepatitis C virus patients before and after treatment and to investigate the relationship between major depressive disorder and generalized anxiety disorder and treatment response.
Methods
A total of 116 consecutive hepatitis C virus patients from hepatitis C virus treatment center in Zagazig city, Egypt, were included in the study and divided into treated group ( N = 58) and untreated group ( N = 58). All hepatitis C virus patients were screened for major depressive disorder and generalized anxiety disorder using hospital anxiety and depression scale, and those who screened positive were interviewed to confirm the diagnosis of major depressive disorder and generalized anxiety disorder using DSM-IV-TR diagnostic criteria. These measures were done at baseline and after 12 weeks of treatment or observation.
Results
At baseline, 3.5% and 12.1% of hepatitis C virus patients (treated group) had major depressive disorder and generalized anxiety disorder, respectively. After 12 weeks of treatment 37.9% of hepatitis C virus patients (treated group) had major depressive disorder and 46.6% had generalized anxiety disorder. There was a significant statistical difference between hospital anxiety and depression scale scores for depression (3.3 ± 2.3 vs. 6.4 ± 3.2, t = 9.6, p = 0.001) and for anxiety (4.6 ± 2.4 vs. 7.3 ± 3.0, t = 10.2, p = 0.001) before and after treatment. There was also significant statistical difference between treated group and untreated group regarding hospital anxiety and depression scale scores after treatment and observation (depression, treated group 6.4 ± 3.2 vs. untreated group 4.0 ± 2.4, t = 3.7, p = 0.001; anxiety, treated group 7.3 ± 3.0 vs. untreated group 4.5 ± 2.3, t = 4.4, p = 0.001). There was no association between major depressive disorder and generalized anxiety disorder and treatment response.
Conclusions
Major depressive disorder and generalized anxiety disorder are common in hepatitis C virus patients after treatment with interferon and ribavirin and were not related to treatment response.
Title: Major depressive disorder and generalized anxiety disorder and response to treatment in hepatitis C patients in Egypt
Description:
Objectives
The aim of the study was to estimate the prevalence and associated correlates of major depressive disorder and generalized anxiety disorder in hepatitis C virus patients before and after treatment and to investigate the relationship between major depressive disorder and generalized anxiety disorder and treatment response.
Methods
A total of 116 consecutive hepatitis C virus patients from hepatitis C virus treatment center in Zagazig city, Egypt, were included in the study and divided into treated group ( N = 58) and untreated group ( N = 58).
All hepatitis C virus patients were screened for major depressive disorder and generalized anxiety disorder using hospital anxiety and depression scale, and those who screened positive were interviewed to confirm the diagnosis of major depressive disorder and generalized anxiety disorder using DSM-IV-TR diagnostic criteria.
These measures were done at baseline and after 12 weeks of treatment or observation.
Results
At baseline, 3.
5% and 12.
1% of hepatitis C virus patients (treated group) had major depressive disorder and generalized anxiety disorder, respectively.
After 12 weeks of treatment 37.
9% of hepatitis C virus patients (treated group) had major depressive disorder and 46.
6% had generalized anxiety disorder.
There was a significant statistical difference between hospital anxiety and depression scale scores for depression (3.
3 ± 2.
3 vs.
6.
4 ± 3.
2, t = 9.
6, p = 0.
001) and for anxiety (4.
6 ± 2.
4 vs.
7.
3 ± 3.
0, t = 10.
2, p = 0.
001) before and after treatment.
There was also significant statistical difference between treated group and untreated group regarding hospital anxiety and depression scale scores after treatment and observation (depression, treated group 6.
4 ± 3.
2 vs.
untreated group 4.
0 ± 2.
4, t = 3.
7, p = 0.
001; anxiety, treated group 7.
3 ± 3.
0 vs.
untreated group 4.
5 ± 2.
3, t = 4.
4, p = 0.
001).
There was no association between major depressive disorder and generalized anxiety disorder and treatment response.
Conclusions
Major depressive disorder and generalized anxiety disorder are common in hepatitis C virus patients after treatment with interferon and ribavirin and were not related to treatment response.
Related Results
The Impact of IL28B Gene Polymorphisms on Drug Responses
The Impact of IL28B Gene Polymorphisms on Drug Responses
To achieve high therapeutic efficacy in the patient, information on pharmacokinetics, pharmacodynamics, and pharmacogenetics is required. With the development of science and techno...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
IgM antibody to hepatitis C virus in acute and chronic hepatitis C
IgM antibody to hepatitis C virus in acute and chronic hepatitis C
To assess possible role of testing for IgM-specific antibody in the diagnosis and monitoring of patients with hepatitis C, we tested sera from 14 patients with acute and 97 patient...
Stress and Depressive Symptoms in College Students: The Sequential Mediating Roles of Emotion Dysregulation and Anxiety (Preprint)
Stress and Depressive Symptoms in College Students: The Sequential Mediating Roles of Emotion Dysregulation and Anxiety (Preprint)
BACKGROUND
Depressive symptoms (DPS) are a prevalent mental health concern among college students. Stress (STR) has been widely identified as an important correla...
Prevalence of Hepatitis C Virus Infection in Hemodialysis Patients: A Longitudinal Study Comparing the Results of RNA and Antibody Assays
Prevalence of Hepatitis C Virus Infection in Hemodialysis Patients: A Longitudinal Study Comparing the Results of RNA and Antibody Assays
We longitudinally studied 51 patients from two hemodialysis centers to determine the prevalence of hepatitis C virus infection in hemodialysis patients. Serum samples were tested f...
P1333 Patients with Inflammatory Bowel Disease exhibit poor response to Hepatitis B vaccination but maintain protective Measles antibody titres
P1333 Patients with Inflammatory Bowel Disease exhibit poor response to Hepatitis B vaccination but maintain protective Measles antibody titres
Abstract
Background
Patients with inflammatory bowel disease (IBD) are prone to infections due to disease activity, malnu...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Hepatitis C Viremia in Patients With Hepatitis C Virus Infection
Hepatitis C Viremia in Patients With Hepatitis C Virus Infection
Sera from 103 patients were tested for hepatitis C virus RNA by nested polymerase chain reaction assay. Using primers from the highly conserved 5′untranslated region, we detected h...

